How should we manage abemaciclib in the peri-operative period during secondary breast reconstruction: balancing oncologic benefit and surgical safety
{{output}}
Abemaciclib, a CDK4/6 inhibitor, has emerged as a pivotal therapy in hormone receptor-positive, HER2-negative breast cancer, including in the adjuvant setting for high-risk early disease. Its integration into long-term oncologic strategies poses new challenges... ...
